RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.» Read More
CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...
NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Bristol-Myers Squibb Co., up $1.88 to $66.48. OMG Group Inc., up $7.50 to $34.04.
The National Cancer Institute's NCI-MATCH trial will be a massive precision medicine experiment at more than 2,400 sites around the country. Douglas Lowy, the Cancer Institute's acting director. Details of the study were revealed Monday at an American Society of Clinical Oncology conference in Chicago.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
*Humana hits record on takeover interest. *Altera rises on report of Intel interest. May 29- U.S. stocks closed lower on Friday as data showed the economy contracted in the first quarter but indexes still posted gains for the month.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
CHICAGO— For the first time, a major study shows that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer. Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Chicago meeting.
BRISTOL-MYERS SQUIBB'S OPDIVO EXTENDS SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...
New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.
The "Fast Money" traders give their final trades of the day.
May 22- EU Medicines Agency:. *EU Medicines Agency recommendations for May 2015. *Recommends approval of cholesterol drug Repatha from Amgen Inc.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...
Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.
That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.